Return to search results.
Complete title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980s) in combination with rituximab or polatuzumab vedotin (DCDS4501a) in combination with rituximab and a non-randomized phase Ib/II evaluation of polatuzumab vedotin in combination with obtinutuzumab in patients with relapsed or refractory B-cell non-Hodgkins's lymphoma
|Research Study Number||2649.00|
|Principal Investigator||Oliver Press, MD, PhD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Immunotherapy
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.